Updated Aug 14 at 10:51am ET.
Follow Centene to never miss an important update.
Centene released its second quarter results, which track how the business is performing as it navigates a shifting Medicaid landscape. These reports are the primary way for owners to see if the company is keeping its medical costs under control and successfully moving members into its commercial marketplace plans.
The filing also noted changes to the executive team. For a company focused on simplifying its operations and selling off smaller units, leadership stability is important to ensure the strategy stays on track. While the filing covers several updates, the core focus remains on how well Centene is managing the health benefit ratio, which is the portion of premiums it spends on medical care.
Source: 8-K filing
Bernstein analysts increased their price target for the company to $79, up from $68, following a strong quarterly report. This new target is well above the average analyst target of $66 and the current price of about $64.
The firm kept its outperform rating, which is their way of saying they expect the stock to do better than the rest of the market. This move suggests growing confidence that the company is managing its costs effectively even as it navigates changes in government-sponsored health programs.
Source: Bernstein
Baird analysts raised their price target for the stock to $66, up from $46. This large jump follows a quarter where the company significantly beat profit expectations and raised its outlook for the rest of the year.
While the new target is close to the current stock price, the size of the increase shows that analysts are quickly adjusting their views. They are recognizing that the business is more resilient than previously thought as it manages the transition of Medicaid members.
Source: Robert W. Baird
Barclays analysts raised their price target to $80, one of the highest on Wall Street, while maintaining an overweight rating. This rating means they believe the stock should make up a larger portion of a portfolio than its size in the market would suggest.
The increase reflects a positive view of the company's ability to control medical costs. When an insurer keeps its health benefit ratio, the percentage of premiums it pays out for medical care, lower than expected, it leaves more profit for the business and its owners.
Source: Barclays
Kenneth A. Burdick retired from the company's board of directors on July 28. Burdick is a former executive at the company, having joined when it acquired WellCare. While board changes are routine, his departure marks the exit of a leader with deep experience in the managed care industry.
Source: PRNewsWire
Analysts have recently raised their price targets for the stock following a steady stream of positive reports throughout the summer. Most analysts rate it a buy, and the average target price is currently equal to the stock's price.
Management has a habit of setting a bar they can clear, beating expectations in seven of the last eight quarters by a wide margin.
| Expectation | |
|---|---|
| EPS | $0.10 |
| Revenue | $47.11B |
